Atlas Trials

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Clinical trial NCT02946385 · COMPLETED

Trial details

NCT number
NCT02946385
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Infections, Meningococcal
Start date
2016-11-15
Primary completion
2018-02-13
Enrollment
604

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.